Ongoing Clinical Trials for Lichen Sclerosus
There are currently 2 clinical trials studying new treatments for lichen sclerosus, a chronic skin condition that primarily affects the genital area. These trials are taking place in Denmark and Poland, testing topical medications including corticosteroids and calcineurin inhibitors to help reduce inflammation, itching, and other symptoms associated with the condition.
Clinical trial locations
- Denmark
- Poland
Study on Clobetasol, Mometasone, and Tacrolimus for Treating Vulvar Lichen Sclerosus in Children
This clinical trial is being conducted in Poland and focuses on treating vulvar lichen sclerosus in children and teenagers. The study compares three different topical ointments to determine which provides the best symptom relief while remaining safe for young patients.
Main inclusion criteria: Participants must be between 2 and 18 years old with a confirmed diagnosis of vulval lichen sclerosus. They need to be in good general health based on a physical examination and have normal levels of certain hormones. Parents or legal representatives must provide consent, and children aged 13 or older must also give their own consent. Participants must score at least 1 point on the symptom severity scale and be able to follow the study requirements. There should be at least a 2-week gap between any vaccination and starting the study medication.
Main exclusion criteria: Only female patients with a confirmed clinical diagnosis of vulval lichen sclerosus within the specified age range can participate. Male patients and those outside the age range cannot join. Patients who are not part of the vulnerable population selected for this study are also excluded.
Focus of the trial: The study aims to evaluate the effectiveness and safety of three different treatments over 12 weeks. Participants are randomly assigned to receive one of three ointments: clobetasol propionate, mometasone furoate, or tacrolimus. The main goal is to achieve at least a 75% reduction in symptoms and a 50% improvement in quality of life after 12 weeks of treatment. Researchers will monitor progress through regular follow-up visits and conduct a long-term evaluation 15 months after starting treatment to assess whether improvements are maintained.
Investigational drugs: The trial tests three medications. Clobetasol is a strong corticosteroid that reduces inflammation and relieves itching and redness by suppressing the immune response. Mometasone is another corticosteroid that helps reduce inflammation and ease symptoms such as itching and swelling. Tacrolimus is a calcineurin inhibitor that works by suppressing the immune system to reduce inflammation, offering a different approach to treatment.
Study on the Effectiveness and Safety of MC2-25 Cream for Women with Vulvar Lichen Sclerosus
This trial is taking place in Denmark and studies a new treatment called MC2-25 cream for adult women with vulvar lichen sclerosus. The study uses a double-blind design, meaning neither participants nor researchers know who receives the active treatment versus a placebo cream.
Main inclusion criteria: Women must be 18 years or older of any race or ethnicity with a clinical diagnosis of vulvar lichen sclerosus confirmed by a dermatologist or gynecologist familiar with the condition. They must show at least one visible sign of the condition, such as bright white patches with a powdery texture or smooth, waxy, yellowish-white areas on the vulva. Symptoms like itching or pain must have been present for at least 6 months before joining. Participants must record at least four itch scores in a diary before the study starts and have moderate to severe itching, defined as an average score of 4 or more. Women of childbearing potential must use reliable birth control and have a negative pregnancy test before starting. Women who are post-menopausal or surgically sterile are also eligible.
Main exclusion criteria: Only women with vulvar lichen sclerosus within the specified age range can participate. Men cannot join this study. Patients belonging to certain vulnerable populations may not be eligible.
Focus of the trial: The study evaluates whether MC2-25 cream, which contains alanyl glutamine as the active ingredient, provides better symptom relief than a cream without the active ingredient. The treatment phase lasts 12 weeks, during which participants apply the cream daily to affected areas and keep a diary recording their itch and pain scores. Researchers measure changes using the Worst Itch Numeric Rating Score and Worst Pain Numeric Rating Score. The main goal is to see if the active cream provides significant relief compared to the placebo. Participants also complete a quality of life questionnaire called the Skindex-29 to assess how treatment affects their daily life.
Investigational drug: MC2-25 cream is a topical anti-inflammatory medication applied directly to the affected vulvar area. It works by modulating inflammatory pathways in the skin to reduce inflammation and discomfort. The trial aims to determine how well this new approach works for managing symptoms of vulvar lichen sclerosus in adult women.
Summary
Currently, there are two ongoing clinical trials for lichen sclerosus, taking place in Denmark and Poland. These studies reflect different approaches to treating the condition across different age groups. The Polish trial focuses specifically on pediatric patients aged 2 to 18, comparing three established topical treatments: two corticosteroids (clobetasol and mometasone) and one calcineurin inhibitor (tacrolimus). In contrast, the Danish trial studies adult women and tests a novel cream containing alanyl glutamine.
Both trials emphasize the importance of reducing key symptoms such as itching and pain while improving quality of life. The pediatric study includes a longer follow-up period of 15 months to assess whether treatment benefits are sustained over time. Both studies require participants to maintain symptom diaries, which helps researchers track treatment effectiveness in real-world conditions.
These trials represent important research efforts to identify safe and effective treatments for a condition that can significantly impact patients’ comfort and daily functioning. The limited number of trials highlights the need for continued research in this area, particularly for developing treatments tailored to different patient populations.
